Association of cys 311 ser polymorphism of paraoxonase-2 gene with the risk of coronary artery disease.

BACKGROUND Recently another member of the paraoxonase gene family designated paraoxonase-2 has been identified. Paraoxonase-2 has antioxidant properties similar to paraoxonase-1 and paraoxonase-3. However, in contrast to paraoxonase-1 and paraoxonase-3, paraoxonase-2 is not associated with high-density lipoprotein and may only exert its antioxidant function at the cellular level. METHODS We assessed the frequency and genotype distribution of cys 311 ser paraoxonase-2 polymorphism in 300 subjects (>40 years old) with angiographic documentation of coronary artery disease (150 patients with >50% stenosis served as cases and 150 individuals with <20% stenosis served as controls) to determine the possible association between this mutation and susceptibility for coronary artery disease. The paraoxonase-2 genotypes were determined by polymerase chain reaction and DdeI restriction enzyme digestion. RESULTS The cases (coronary artery disease positive patients) showed significant differences in the distribution of cys 311 ser paraoxonase-2 genotypes as compared with the controls (coronary artery disease negative subjects, P=0.015). The analysis of paraoxonase-2 genotypes distribution showed higher percentage of CC genotype among coronary artery disease positive compared with coronary artery disease negative (P=0.008). After controlling for other risk factors, the cys 311 ser polymorphism had not correlation with age, body mass index, gender, smoking, diabetes, level of high-density lipoprotein, low-density lipoprotein, triglyceride, and total cholesterol. CONCLUSION Our data indicate a major effect of the paraoxonase-2 polymorphism on coronary artery disease risk in patients referred to Shariati Hospital in Tehran.

[1]  P. Durrington,et al.  Paraoxonase and coronary heart disease. , 1998, Atherosclerosis. Supplements.

[2]  E. Trabetti,et al.  Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction , 2004, European journal of clinical investigation.

[3]  P. Edwards,et al.  The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[4]  M. Jauhiainen,et al.  The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns. , 1996, The Journal of clinical investigation.

[5]  S. Reddy,et al.  Paraoxonase-2 Is a Ubiquitously Expressed Protein with Antioxidant Properties and Is Capable of Preventing Cell-mediated Oxidative Modification of Low Density Lipoprotein* , 2001, The Journal of Biological Chemistry.

[6]  D. Shih,et al.  Human Paraoxonase-3 Is an HDL-Associated Enzyme With Biological Activity Similar to Paraoxonase-1 Protein but Is Not Regulated by Oxidized Lipids , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Dan S. Tawfik,et al.  Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes , 2004, Nature Structural &Molecular Biology.

[8]  D. Sanghera,et al.  DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. , 1998, American journal of human genetics.

[9]  S. Scherer,et al.  Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. , 1998, Atherosclerosis.

[10]  S. Scherer,et al.  Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. , 1998, Gene.

[11]  B. La Du,et al.  The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.

[12]  J. Kastelein,et al.  PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. , 2001, Atherosclerosis.

[13]  A. Marciniak,et al.  Species- and substrate-specific stimulation of human plasma paraoxonase 1 (PON1) activity by high chloride concentration. , 2002, Acta biochimica Polonica.

[14]  B. La Du,et al.  Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. , 1998, The Journal of clinical investigation.

[15]  M. Price,et al.  New strategies in managing and preventing atherosclerosis: focus on HDL. , 2002, Reviews in cardiovascular medicine.

[16]  M. Keifer,et al.  The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin , 1996, Nature Genetics.

[17]  S. Reis,et al.  Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. , 2003, American journal of human genetics.

[18]  C. Abbott,et al.  Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.